Compared with placebo, the 0.05 mg and 0.1 mg estradiol groups showed a statistically significantly larger mean decrease in hot flushes across all treatment cycles (P 0.9 gm/cm2) women at 10 study centers in the United States
Certain groups should exercise caution or avoid MIC injections, including individuals with heart conditions, pregnant or breastfeeding women, and those with liver disease, kidney problems, or metabolic disorders
The Nuun immunity line comes with zinc, but not the Sport Line
M.BiolattoA.SanchoA
14 proposed a change in nomenclature to metabolic-associated fatty liver disease or MAFLD
Clinical Safety of GLP-1 Therapy Post-Gastric Bypass Limited direct clinical trial data exists on Tirzepatide use in post-bariatric patients, but observational data and extrapolation from GLP-1 receptor agonist studies suggest injection-based GLP-1 therapy is generally safe in this population